Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the sale, the chief operating officer now owns 732,294 shares of the company’s stock, valued at $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00.

Roivant Sciences Trading Down 1.0 %

Shares of ROIV opened at $11.16 on Thursday. The business’s 50 day moving average is $11.75 and its 200 day moving average is $11.60. Roivant Sciences Ltd. has a 12-month low of $9.69 and a 12-month high of $13.06. The company has a market capitalization of $8.12 billion, a PE ratio of 1.98 and a beta of 1.27.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.93.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. TOMS Capital Investment Management LP purchased a new position in Roivant Sciences during the third quarter valued at $46,333,000. Troluce Capital Advisors LLC purchased a new position in shares of Roivant Sciences during the second quarter valued at about $31,182,000. FMR LLC increased its holdings in shares of Roivant Sciences by 5.6% in the third quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after buying an additional 1,460,205 shares in the last quarter. Finally, BlackBarn Capital Partners LP boosted its stake in Roivant Sciences by 63.1% during the second quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock valued at $32,767,000 after buying an additional 1,199,406 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.